Travere Therapeutics Analyst Ratings
Travere Therapeutics Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 09/29/2023 | 31.58% | Wedbush | → $12 | Reiterates | Outperform → Outperform |
| 09/22/2023 | 31.58% | Barclays | $31 → $12 | Maintains | Overweight |
| 09/22/2023 | 196.05% | B of A Securities | $41 → $27 | Maintains | Buy |
| 09/22/2023 | 97.37% | Guggenheim | $25 → $18 | Maintains | Buy |
| 09/22/2023 | 53.51% | Evercore ISI Group | $30 → $14 | Maintains | Outperform |
| 09/22/2023 | 97.37% | HC Wainwright & Co. | $32 → $18 | Maintains | Buy |
| 09/22/2023 | -12.28% | Wells Fargo | $24 → $8 | Downgrades | Overweight → Equal-Weight |
| 09/21/2023 | — | William Blair | Downgrades | Outperform → Market Perform | |
| 09/19/2023 | 228.95% | Evercore ISI Group | $30 → $30 | Maintains | Outperform |
| 09/06/2023 | 228.95% | Evercore ISI Group | → $30 | Reinstates | Outperform → Outperform |
| 08/18/2023 | 108.33% | Piper Sandler | $22 → $19 | Maintains | Neutral |
| 08/07/2023 | 250.88% | HC Wainwright & Co. | $35 → $32 | Reiterates | Buy → Buy |
| 07/21/2023 | 185.09% | JP Morgan | → $26 | Initiates Coverage On | → Overweight |
| 07/18/2023 | 283.77% | Canaccord Genuity | $37 → $35 | Maintains | Buy |
| 06/21/2023 | 152.19% | Wedbush | → $23 | Reiterates | Outperform → Outperform |
| 06/07/2023 | 141.23% | Piper Sandler | → $22 | Assumes | → Neutral |
| 06/01/2023 | 283.77% | HC Wainwright & Co. | $22 → $35 | Reiterates | → Buy |
| 05/22/2023 | 228.95% | TD Cowen | → $30 | Initiates Coverage On | → Outperform |
| 05/02/2023 | 141.23% | HC Wainwright & Co. | $40 → $22 | Maintains | Buy |
| 05/02/2023 | 327.63% | B of A Securities | $52 → $39 | Maintains | Buy |
| 05/02/2023 | 185.09% | Evercore ISI Group | $36 → $26 | Maintains | Outperform |
| 05/02/2023 | 163.16% | Wells Fargo | $28 → $24 | Maintains | Overweight |
| 05/02/2023 | 152.19% | Guggenheim | $40 → $23 | Maintains | Buy |
| 04/17/2023 | 217.98% | Wedbush | $30 → $29 | Maintains | Outperform |
| 03/01/2023 | 305.7% | Guggenheim | → $37 | Initiates Coverage On | → Buy |
| 02/28/2023 | 360.53% | Canaccord Genuity | $44 → $42 | Maintains | Buy |
| 02/24/2023 | 338.6% | HC Wainwright & Co. | → $40 | Reiterates | → Buy |
| 02/22/2023 | 382.46% | Canaccord Genuity | $40 → $44 | Maintains | Buy |
| 02/21/2023 | 404.39% | Piper Sandler | $42 → $46 | Maintains | Overweight |
| 02/21/2023 | 228.95% | Wedbush | → $30 | Upgrades | Neutral → Outperform |
| 02/21/2023 | 239.91% | Barclays | $37 → $31 | Maintains | Overweight |
| 02/21/2023 | 338.6% | HC Wainwright & Co. | $36 → $40 | Reiterates | → Buy |
| 02/17/2023 | 294.74% | HC Wainwright & Co. | → $36 | Reiterates | → Buy |
| 01/30/2023 | 338.6% | Canaccord Genuity | $33 → $40 | Maintains | Buy |
| 01/11/2023 | 360.53% | Piper Sandler | $38 → $42 | Maintains | Overweight |
| 12/14/2022 | 141.23% | Stifel | → $22 | Initiates Coverage On | → Hold |
| 12/05/2022 | 207.02% | Wells Fargo | → $28 | Initiates Coverage On | → Overweight |
| 10/20/2022 | 316.67% | SVB Leerink | $45 → $38 | Maintains | Outperform |
| 10/17/2022 | 294.74% | HC Wainwright & Co. | $42 → $36 | Maintains | Buy |
| 10/14/2022 | 316.67% | Piper Sandler | $39 → $38 | Maintains | Overweight |
| 08/08/2022 | 360.53% | HC Wainwright & Co. | $46 → $42 | Maintains | Buy |
| 08/05/2022 | 393.42% | SVB Leerink | $42 → $45 | Maintains | Outperform |
| 07/26/2022 | 349.56% | Piper Sandler | $40 → $41 | Maintains | Overweight |
| 07/14/2022 | 360.53% | Canaccord Genuity | → $42 | Assumes | → Buy |
| 05/17/2022 | 404.39% | HC Wainwright & Co. | $45 → $46 | Maintains | Buy |
| 05/06/2022 | 338.6% | Piper Sandler | $42 → $40 | Maintains | Overweight |
| 03/31/2022 | 360.53% | Piper Sandler | → $42 | Initiates Coverage On | → Overweight |
| 02/28/2022 | 393.42% | HC Wainwright & Co. | → $45 | Initiates Coverage On | → Buy |
| 12/16/2021 | 338.6% | Barclays | $36 → $40 | Maintains | Overweight |
| 12/16/2021 | 360.53% | SVB Leerink | $37 → $42 | Maintains | Outperform |
| 08/17/2021 | 305.7% | SVB Leerink | $27 → $37 | Maintains | Outperform |
| 05/27/2021 | 393.42% | Canaccord Genuity | $48 → $45 | Maintains | Buy |
| 05/26/2021 | 108.33% | Wedbush | → $19 | Downgrades | Outperform → Neutral |
| 05/17/2021 | 426.32% | Canaccord Genuity | $51 → $48 | Maintains | Buy |
| 02/03/2021 | 459.21% | Canaccord Genuity | $28 → $51 | Maintains | Buy |
| 日期 | 上行/下行 | 分析公司 | 目标价格变化 | 评级变化 | 上一次/当前评级 |
|---|---|---|---|---|---|
| 09/29/2023 | 31.58% | 韦德布什 | →$12 | 重申 | 跑赢→跑赢大盘 |
| 09/22/2023 | 31.58% | 巴克莱 | $31→$12 | 维护 | 超重 |
| 09/22/2023 | 196.05% | B of A证券 | $41→$27 | 维护 | 买 |
| 09/22/2023 | 97.37% | 古根海姆 | $25→$18 | 维护 | 买 |
| 09/22/2023 | 53.51% | Evercore ISI集团 | $30→$14 | 维护 | 跑赢大盘 |
| 09/22/2023 | 97.37% | HC Wainwright公司 | $32→$18 | 维护 | 买 |
| 09/22/2023 | -12.28% | 富国银行 | $24→$8 | 评级下调 | 超重→等重 |
| 2023年09月21日 | - | 威廉·布莱尔 | 评级下调 | 跑赢→市场表现 | |
| 2023/09/19 | 228.95% | Evercore ISI集团 | $30→$30 | 维护 | 跑赢大盘 |
| 09/06/2023 | 228.95% | Evercore ISI集团 | →$30 | 恢复 | 跑赢→跑赢大盘 |
| 2023年08月18日 | 108.33% | 派珀·桑德勒 | $22→$19 | 维护 | 中性 |
| 08/07/2023 | 250.88% | HC Wainwright公司 | $35→$32 | 重申 | 购买→购买 |
| 07/21/2023 | 185.09% | 摩根大通 | →$26 | 开始承保 | →超重 |
| 07/18/2023 | 283.77% | 卡纳科特·格纳奇 | $37→$35 | 维护 | 买 |
| 2023年6月21日 | 152.19% | 韦德布什 | →$23 | 重申 | 跑赢→跑赢大盘 |
| 06/07/2023 | 141.23% | 派珀·桑德勒 | →$22 | 假设 | →中性 |
| 06/01/2023 | 283.77% | HC Wainwright公司 | $22→$35 | 重申 | →购买 |
| 2023年05月22日 | 228.95% | TD Cowen | →$30 | 开始承保 | →跑赢大盘 |
| 05/02/2023 | 141.23% | HC Wainwright公司 | $40→$22 | 维护 | 买 |
| 05/02/2023 | 327.63% | B of A证券 | $52→$39 | 维护 | 买 |
| 05/02/2023 | 185.09% | Evercore ISI集团 | $36→$26 | 维护 | 跑赢大盘 |
| 05/02/2023 | 163.16% | 富国银行 | $28→$24 | 维护 | 超重 |
| 05/02/2023 | 152.19% | 古根海姆 | $40→$23 | 维护 | 买 |
| 04/17/2023 | 217.98% | 韦德布什 | $30→$29 | 维护 | 跑赢大盘 |
| 03/01/2023 | 305.7% | 古根海姆 | →$37 | 开始承保 | →购买 |
| 02/28/2023 | 360.53% | 卡纳科特·格纳奇 | $44→$42 | 维护 | 买 |
| 02/24/2023 | 338.6% | HC Wainwright公司 | →$40 | 重申 | →购买 |
| 02/22/2023 | 382.46% | 卡纳科特·格纳奇 | $40→$44 | 维护 | 买 |
| 02/21/2023 | 404.39% | 派珀·桑德勒 | $42→$46 | 维护 | 超重 |
| 02/21/2023 | 228.95% | 韦德布什 | →$30 | 升级 | 中性→表现优异 |
| 02/21/2023 | 239.91% | 巴克莱 | $37→$31 | 维护 | 超重 |
| 02/21/2023 | 338.6% | HC Wainwright公司 | $36→$40 | 重申 | →购买 |
| 02/17/2023 | 294.74% | HC Wainwright公司 | →$36 | 重申 | →购买 |
| 2023年1月30日 | 338.6% | 卡纳科特·格纳奇 | $33→$40 | 维护 | 买 |
| 2023年1月11日 | 360.53% | 派珀·桑德勒 | $38→$42 | 维护 | 超重 |
| 2022年12月14日 | 141.23% | Stifel | →$22 | 开始承保 | →保留 |
| 12/05/2022 | 207.02% | 富国银行 | →$28 | 开始承保 | →超重 |
| 10/20/2022 | 316.67% | SVB Leerink | $45→$38 | 维护 | 跑赢大盘 |
| 10/17/2022 | 294.74% | HC Wainwright公司 | $42→$36 | 维护 | 买 |
| 10/14/2022 | 316.67% | 派珀·桑德勒 | $39→$38 | 维护 | 超重 |
| 2022/08/08 | 360.53% | HC Wainwright公司 | $46→$42 | 维护 | 买 |
| 08/05/2022 | 393.42% | SVB Leerink | $42→$45 | 维护 | 跑赢大盘 |
| 07/26/2022 | 349.56% | 派珀·桑德勒 | $40→$41 | 维护 | 超重 |
| 07/14/2022 | 360.53% | 卡纳科特·格纳奇 | →$42 | 假设 | →购买 |
| 2022/05/17 | 404.39% | HC Wainwright公司 | $45→$46 | 维护 | 买 |
| 05/06/2022 | 338.6% | 派珀·桑德勒 | $42→$40 | 维护 | 超重 |
| 03/31/2022 | 360.53% | 派珀·桑德勒 | →$42 | 开始承保 | →超重 |
| 02/28/2022 | 393.42% | HC Wainwright公司 | →$45 | 开始承保 | →购买 |
| 12/16/2021 | 338.6% | 巴克莱 | $36→$40 | 维护 | 超重 |
| 12/16/2021 | 360.53% | SVB Leerink | $37→$42 | 维护 | 跑赢大盘 |
| 2021/08/17 | 305.7% | SVB Leerink | $27→$37 | 维护 | 跑赢大盘 |
| 2021/05/27 | 393.42% | 卡纳科特·格纳奇 | $48→$45 | 维护 | 买 |
| 2021/05/26 | 108.33% | 韦德布什 | →$19 | 评级下调 | 跑赢→中性 |
| 2021/05/17 | 426.32% | 卡纳科特·格纳奇 | $51→$48 | 维护 | 买 |
| 02/03/2021 | 459.21% | 卡纳科特·格纳奇 | $28→$51 | 维护 | 买 |
What is the target price for Travere Therapeutics (TVTX)?
Travere Treeutics(TVTX)的目标价格是多少？
The latest price target for Travere Therapeutics (NASDAQ: TVTX) was reported by Wedbush on September 29, 2023. The analyst firm set a price target for $12.00 expecting TVTX to rise to within 12 months (a possible 31.58% upside). 40 analyst firms have reported ratings in the last year.
韦德布什于2023年9月29日报道了Travere治疗公司(纳斯达克：TVTX)的最新目标价。这家分析公司将目标价定为12.00美元，预计TVTX将在12个月内上涨(可能上涨31.58%)。去年，已有40家分析公司公布了评级。
What is the most recent analyst rating for Travere Therapeutics (TVTX)?
Travere Treeutics(TVTX)的最新分析师评级是什么？
The latest analyst rating for Travere Therapeutics (NASDAQ: TVTX) was provided by Wedbush, and Travere Therapeutics reiterated their outperform rating.
Travere Treeutics(纳斯达克股票代码：TVTX)的最新分析师评级是由韦德布什公司提供的，Travere治疗公司重申了他们的表现优于大盘的评级。
When is the next analyst rating going to be posted or updated for Travere Therapeutics (TVTX)?
Travere Treeutics(TVTX)的下一次分析师评级将于何时发布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Travere Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Travere Therapeutics was filed on September 29, 2023 so you should expect the next rating to be made available sometime around September 29, 2024.
分析师在进行了广泛的研究后得出股票评级，其中包括查阅公共财务报表，与Travere Treeutics的高管和客户交谈，以及听取收益电话会议。大多数分析师每三个月就会这样做一次，所以你每年应该会得到每家公司每家公司的4个评级。Travere治疗公司的上一次评级是在2023年9月29日提交的，所以你应该预计下一次评级将在2024年9月29日左右的某个时候提供。
Is the Analyst Rating Travere Therapeutics (TVTX) correct?
分析师对Travere Treeutics(TVTX)的评级正确吗？
While ratings are subjective and will change, the latest Travere Therapeutics (TVTX) rating was a reiterated with a price target of $0.00 to $12.00. The current price Travere Therapeutics (TVTX) is trading at is $9.12, which is within the analyst's predicted range.
虽然评级是主观的，并将发生变化，但最新的Travere Treateutics(TVTX)评级被重申，目标价在0.00美元至12.00美元之间。Travere Treateutics(TVTX)目前的交易价格为9.12美元，在分析师的预测范围内。